TY - JOUR
T1 - Impact of High-Frequency HLA Haplotypes on Clinical Cytomegalovirus Reactivation in Allogeneic Hematopoietic Stem Cell Transplantation
AU - HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation
AU - Kawase, Takakazu
AU - Tanaka, Hidenori
AU - Kojima, Hiroto
AU - Uchida, Naoyuki
AU - Ohashi, Kazuteru
AU - Fukuda, Takahiro
AU - Ozawa, Yukiyasu
AU - Ikegame, Kazuhiro
AU - Eto, Tetsuya
AU - Mori, Takehiko
AU - Miyamoto, Toshihiro
AU - Hidaka, Michihiro
AU - Shiratori, Souichi
AU - Takanashi, Minoko
AU - Atsuta, Yoshiko
AU - Ichinohe, Tatsuo
AU - Kanda, Yoshinobu
AU - Kanda, Junya
N1 - Funding Information:
The authors thank all of the physicians and data managers at the centers that contributed transplantation data to the Japanese Data Center for Hematopoietic Cell Transplantation. Financial disclosure: Tatsuo Ichinohe Research funding: Astellas Pharma, Chugai Pharmaceutical Co. CSL Behring, Eisai Co. Kyowa Hakko Kirin Co. Ono Pharmaceutical Co. Pfizer, Nippon Shinyaku Co. MSD, Otsuka Pharmaceutical Co. Repertoire Genesis Inc. Sumitomo Dainippon Pharma Co. Taiho Pharmaceutical Co. Takeda Pharmaceutical Co. and Zenyaku Kogyo Co. Honoraria directly received from an entity: Alexion Pharmaceuticals, Bristol-Myers Squibb, Celgene, JCR Pharmaceuticals, Janssen Pharmaceutical K.K. Mundipharma, and Novartis. Conflict of interest statement: There are no conflicts of interest to report. Authorship statement: T.K. H.T. H.K. T.I. Y.K. and J.K. designed the study. N.U. K.O. T.F. Y.O. K.I. T.E. T.M. T.M. M.H. and S.S. gathered the data. T.K. H.T. H.K. and J.K. analyzed the data. M.I. T.I. and Y.A. managed the database. T.K. H.T. H.K. and J.K. wrote the paper. All authors contributed to the final version.
Publisher Copyright:
© 2019 American Society for Transplantation and Cellular Therapy
PY - 2019/12
Y1 - 2019/12
N2 - Some studies support the hypothesis that HLA genes and haplotypes evolved by natural selection through their protective abilities against specific infectious pathogens. However, very little is known regarding the impact of high-frequency HLA haplotypes on the risk of relevant infectious diseases among a given ethnic group. We evaluated the impact of high-frequency HLA haplotypes on cytomegalovirus (CMV) reactivation and infection in allogeneic hematopoietic stem cell transplantation (allo-HSCT) in a Japanese population as a model of infectious disease that has coexisted with humans. A total of 21,127 donor-patient pairs were analyzed. HLA-A-B-DRB1 haplotypes were estimated using the maximum probability algorithm. Seven haplotypes with >1% frequency were defined as high-frequency haplotypes (HfHPs). Homozygotes of HfHP and heterozygotes had significantly lower risk of CMV reactivation and infection (hazard ratio [HR] = 0.88, P =.009 and HR = 0.93, P =.003, respectively) than homozygotes of low-frequency HLA haplotypes (LfHPs). In subgroup analyses of a different donor source, these associations were statistically significant in unrelated donor transplants. Finally, CMV risk for homozygotes and heterozygotes of each HfHP was compared with that of homozygotes of LfHPs. The 2 most predominant HfHP groups (A*24:02-B*52:01-DRB1*15:02 group and A*24:02-B*07:02-DRB1*01:01 group) had a significantly lower risk of CMV reactivation and infection (HR = 0.86, P <.001 and HR = 0.91, P =.033, respectively). Our findings suggest that HfHPs may be protective against CMV reactivation and infection and that increased care regarding CMV reactivation and infection may be necessary for patients with LfHP after allo-HSCT.
AB - Some studies support the hypothesis that HLA genes and haplotypes evolved by natural selection through their protective abilities against specific infectious pathogens. However, very little is known regarding the impact of high-frequency HLA haplotypes on the risk of relevant infectious diseases among a given ethnic group. We evaluated the impact of high-frequency HLA haplotypes on cytomegalovirus (CMV) reactivation and infection in allogeneic hematopoietic stem cell transplantation (allo-HSCT) in a Japanese population as a model of infectious disease that has coexisted with humans. A total of 21,127 donor-patient pairs were analyzed. HLA-A-B-DRB1 haplotypes were estimated using the maximum probability algorithm. Seven haplotypes with >1% frequency were defined as high-frequency haplotypes (HfHPs). Homozygotes of HfHP and heterozygotes had significantly lower risk of CMV reactivation and infection (hazard ratio [HR] = 0.88, P =.009 and HR = 0.93, P =.003, respectively) than homozygotes of low-frequency HLA haplotypes (LfHPs). In subgroup analyses of a different donor source, these associations were statistically significant in unrelated donor transplants. Finally, CMV risk for homozygotes and heterozygotes of each HfHP was compared with that of homozygotes of LfHPs. The 2 most predominant HfHP groups (A*24:02-B*52:01-DRB1*15:02 group and A*24:02-B*07:02-DRB1*01:01 group) had a significantly lower risk of CMV reactivation and infection (HR = 0.86, P <.001 and HR = 0.91, P =.033, respectively). Our findings suggest that HfHPs may be protective against CMV reactivation and infection and that increased care regarding CMV reactivation and infection may be necessary for patients with LfHP after allo-HSCT.
KW - Allogeneic hematopoietic stem cell transplantation
KW - Cytomegalovirus
KW - HLA haplotypes
UR - http://www.scopus.com/inward/record.url?scp=85072271025&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072271025&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2019.07.042
DO - 10.1016/j.bbmt.2019.07.042
M3 - Article
C2 - 31400501
AN - SCOPUS:85072271025
SN - 1083-8791
VL - 25
SP - 2482
EP - 2489
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 12
ER -